Quick Answer
Xenon Pharmaceuticals Inc. reported Earnings Per Share Diluted of $4.36 (loss) per share for the year ending 2025.
- Xenon Pharmaceuticals Inc. showed a decrease of -44.9% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Xenon Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2012 to 2025), Xenon Pharmaceuticals Inc.'s Earnings Per Share Diluted has declined by 34.6%.
- Historical annual values: Fiscal year 2025: $4.36 (loss) per share | Fiscal year 2024: $3.01 (loss) per share | Fiscal year 2023: $2.73 (loss) per share | Fiscal year 2022: $2.06 (loss) per share | Fiscal year 2021: $1.77 (loss) per share | Fiscal year 2020: $0.81 (loss) per share | Fiscal year 2018: $1.63 (loss) per share | Fiscal year 2017: $1.72 (loss) per share | Fiscal year 2016: $1.48 (loss) per share | Fiscal year 2015: $1.10 (loss) per share | Fiscal year 2014: $3.28 per share | Fiscal year 2013: $1.91 per share | Fiscal year 2012: $3.24 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: